Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Voest EE"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 83
Tytuł:
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Autorzy:
Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
van Berge Henegouwen JM; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
van der Wijngaart H; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands.
van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands.
de Leng WWJ; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands.
Jansen AML; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands.
Opdam FL; Department of Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Cirkel GA; Department of Medical Oncology, Meander, Amersfoort, the Netherlands.
Labots M; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands.
Hoeben A; Department of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Kerver ED; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
Bins AD; Department of Medical Oncology, Amsterdam University Medical Centre, location AUMC, Amsterdam, the Netherlands.
Erdkamp FGL; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geelen, the Netherlands.
van Rooijen JM; Department of Medical Oncology, Martini Hospital, Groningen, the Netherlands.
Houtsma D; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands.
Hendriks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, the Netherlands.
de Groot JB; Department of Medical Oncology, Isala, Zwolle, the Netherlands.
Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.; Oncode Institute, Utrecht, the Netherlands. e.voest@nki.nl.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Mar 04; Vol. 23 (1), pp. 205. Date of Electronic Publication: 2023 Mar 04.
Typ publikacji:
Journal Article
MeSH Terms:
Microsatellite Instability*
Brain Neoplasms*
Humans ; Biomarkers
SCR Disease Name:
Turcot syndrome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.
Autorzy:
Schipper LJ; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.
Monkhorst K; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Samsom KG; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Bosch LJW; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van Boven H; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Roepman P; Hartwig Medical Foundation, 1098 XH Amsterdam, The Netherlands.
van der Kolk LE; Family Cancer Clinic, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van Houdt WJ; Department of Surgical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
van der Graaf WTA; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Meijer GA; Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Jan 16; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 16.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Autorzy:
Samsom KG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bosch LJW; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Schipper LJ; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.
de Bruijn E; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Riethorst I; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Schoenmaker L; Hartwig Medical Foundation, Amsterdam, The Netherlands.
van der Kolk LE; Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Retèl VP
Frederix GWJ
Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van der Hoeven JJM; Hartwig Medical Foundation, Amsterdam, The Netherlands.
Voest EE; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Cuppen E; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, The Netherlands.
Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. .
Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
BMC medical genomics [BMC Med Genomics] 2020 Nov 10; Vol. 13 (1), pp. 169. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji:
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Molecular Diagnostic Techniques*/economics
Molecular Diagnostic Techniques*/methods
Neoplasms*/chemistry
Neoplasms*/diagnosis
Neoplasms*/genetics
Precision Medicine*/methods
Whole Genome Sequencing*/economics
Whole Genome Sequencing*/methods
Humans ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Clinical Decision-Making ; DNA, Neoplasm/genetics ; Feasibility Studies ; Observational Studies as Topic ; Patient Selection ; Research Design ; Specimen Handling/methods ; Standard of Care ; Technology Assessment, Biomedical ; Workflow ; Validation Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Managing unsolicited findings in genomics: A qualitative interview study with cancer patients.
Autorzy:
Bijlsma RM; Cancer Center, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
Wouters RHP; Julius Center, Department of Medical Humanities, University Medical Center Utrecht, Utrecht, Netherlands.
Wessels H; Department of Corporate Communications, University Medical Center Utrecht, Utrecht, Netherlands.
May AM; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
Ausems MGEM; Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands.
Voest EE; Netherlands Cancer Institute Antoni van Leeuwenhoek, Department of Medical Oncology, Amsterdam, Netherlands.
Bredenoord AL; Julius Center, Department of Medical Humanities, University Medical Center Utrecht, Utrecht, Netherlands.
Pokaż więcej
Źródło:
Psycho-oncology [Psychooncology] 2018 Apr; Vol. 27 (4), pp. 1327-1333. Date of Electronic Publication: 2018 Mar 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Genomics*
Family/*psychology
Neoplasms/*psychology
Patient Preference/*psychology
Adaptation, Psychological ; Adult ; Decision Making ; Disclosure ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Middle Aged ; Neoplasms/genetics ; Qualitative Research
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
Autorzy:
de Leng WW; Department of Pathology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Gadellaa-van Hooijdonk CG; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Barendregt-Smouter FA; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Koudijs MJ; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Nijman I; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Hinrichs JW; Department of Pathology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Cuppen E; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
van Lieshout S; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Genetics, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Loberg RD; Medical Sciences, Amgen Inc., Thousand Oaks, CA, 91320-1799, United States of America.
de Jonge M; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, 3075 EA Rotterdam, The Netherlands.
Voest EE; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
de Weger RA; Department of Pathology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Steeghs N; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
Langenberg MH; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
Sleijfer S; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, 3075 EA Rotterdam, The Netherlands.
Willems SM; Department of Pathology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.
Lolkema MP; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.; Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, 3075 EA Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Feb 26; Vol. 11 (2), pp. e0149405. Date of Electronic Publication: 2016 Feb 26 (Print Publication: 2016).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
DNA Mutational Analysis/*methods
High-Throughput Nucleotide Sequencing/*methods
Neoplasms/*genetics
Formaldehyde ; Humans ; Neoplasms/pathology ; Paraffin Embedding ; Reproducibility of Results ; Tissue Fixation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
Autorzy:
Kerklaan BM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lolkema MP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Devriese LA; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Voest EE; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Nol-Boekel A; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mergui-Roelvink M; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Langenberg M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Mykulowycz K; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Stoebenau J; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Lane S; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Legenne P; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Wissel P; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Smith DA; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Giantonio BJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Schellens JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Science Faculty, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Witteveen PO; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 01; Vol. 113 (5), pp. 706-15. Date of Electronic Publication: 2015 Aug 20.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Ovarian Neoplasms/*drug therapy
Pancreatic Neoplasms/*drug therapy
Administration, Oral ; Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Female ; Humans ; Indazoles ; Male ; Maximum Tolerated Dose ; Middle Aged ; Ovarian Neoplasms/pathology ; Pancreatic Neoplasms/pathology ; Pyrimidines/administration & dosage ; Sulfonamides/administration & dosage ; Topotecan/administration & dosage ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.
Autorzy:
Hoogstraat M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; Netherlands Center for Personalized Cancer Treatment, Utrecht, The Netherlands.
Gadellaa-van Hooijdonk CG
Ubink I
Besselink NJ
Pieterse M
Veldhuis W
van Stralen M
Meijer EF
Willems SM
Hadders MA
Kuilman T
Krijgsman O
Peeper DS
Koudijs MJ
Cuppen E
Voest EE
Lolkema MP
Pokaż więcej
Źródło:
Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2015 May; Vol. 28 (3), pp. 318-23. Date of Electronic Publication: 2015 Jan 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Diagnostic Imaging*
Genetic Heterogeneity*
Drug Resistance, Neoplasm/*genetics
Indoles/*therapeutic use
Melanoma/*drug therapy
Mutation/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Sulfonamides/*therapeutic use
Biopsy ; Drug Resistance, Neoplasm/drug effects ; Humans ; Indoles/pharmacology ; Melanoma/genetics ; Melanoma/pathology ; Neoplasm Metastasis ; Sulfonamides/pharmacology ; Vemurafenib
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Autorzy:
Lankheet NA; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.
Gadellaa-van Hooijdonk CG; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Cirkel GA; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Mathijssen RH; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Lolkema MP; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Schellens JH; 1] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands.
Voest EE; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Sleijfer S; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
de Jonge MJ; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Haanen JB; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands.
Beijnen JH; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
Huitema AD; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
Steeghs N; 1] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 May 13; Vol. 110 (10), pp. 2441-9. Date of Electronic Publication: 2014 Apr 15.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Salvage Therapy*
Antineoplastic Agents/*administration & dosage
Indoles/*administration & dosage
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Pyrroles/*administration & dosage
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/blood ; Antineoplastic Agents/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Monitoring ; Fatigue/chemically induced ; Feasibility Studies ; Female ; Gastrointestinal Diseases/chemically induced ; Hematologic Diseases/chemically induced ; Humans ; Indoles/adverse effects ; Indoles/blood ; Indoles/pharmacokinetics ; Male ; Middle Aged ; Neoplasms/enzymology ; Nervous System Diseases/chemically induced ; Pilot Projects ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/blood ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrroles/adverse effects ; Pyrroles/blood ; Pyrroles/pharmacokinetics ; Sunitinib
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.
Autorzy:
Daenen LG; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Houthuijzen JM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Cirkel GA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Roodhart JM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Shaked Y; Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Voest EE; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
Oncogene [Oncogene] 2014 Mar 13; Vol. 33 (11), pp. 1341-7. Date of Electronic Publication: 2013 Mar 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents/*pharmacology
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Mutations in LRRC50 predispose zebrafish and humans to seminomas.
Autorzy:
Basten SG; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Davis EE
Gillis AJ
van Rooijen E
Stoop H
Babala N
Logister I
Heath ZG
Jonges TN
Katsanis N
Voest EE
van Eeden FJ
Medema RH
Ketting RF
Schulte-Merker S
Looijenga LH
Giles RH
Pokaż więcej
Źródło:
PLoS genetics [PLoS Genet] 2013 Apr; Vol. 9 (4), pp. e1003384. Date of Electronic Publication: 2013 Apr 11.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Seminoma*
Zebrafish*/genetics
Animals ; Genes, Tumor Suppressor ; Genotype ; Humans ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial).
Autorzy:
van der Sluis PC; Department of Surgery, G04,228, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, CX, 3584, the Netherlands. />Ruurda JP
van der Horst S
Verhage RJ
Besselink MG
Prins MJ
Haverkamp L
Schippers C
Rinkes IH
Joore HC
Ten Kate FJ
Koffijberg H
Kroese CC
van Leeuwen MS
Lolkema MP
Reerink O
Schipper ME
Steenhagen E
Vleggaar FP
Voest EE
Siersema PD
van Hillegersberg R
Pokaż więcej
Źródło:
Trials [Trials] 2012 Nov 30; Vol. 13, pp. 230. Date of Electronic Publication: 2012 Nov 30.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Laparoscopy*/adverse effects
Laparoscopy*/economics
Laparoscopy*/mortality
Research Design*
Robotics*
Surgery, Computer-Assisted*/adverse effects
Surgery, Computer-Assisted*/economics
Surgery, Computer-Assisted*/mortality
Thoracoscopy*/adverse effects
Thoracoscopy*/economics
Thoracoscopy*/mortality
Adenocarcinoma/*surgery
Carcinoma, Squamous Cell/*surgery
Esophageal Neoplasms/*surgery
Esophagectomy/*methods
Adenocarcinoma/economics ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/economics ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/pathology ; Clinical Protocols ; Cost-Benefit Analysis ; Esophageal Neoplasms/economics ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/pathology ; Esophagectomy/adverse effects ; Esophagectomy/economics ; Esophagectomy/mortality ; Hospital Costs ; Hospital Mortality ; Humans ; Length of Stay ; Lymph Node Excision ; Middle Aged ; Neoplasm Staging ; Netherlands ; Postoperative Complications/mortality ; Quality of Life ; Risk Factors ; Time Factors ; Treatment Outcome ; Young Adult
SCR Disease Name:
Adenocarcinoma Of Esophagus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
Autorzy:
Ploquin A; Centre Oscar Lambret, Medical Oncology Department, 3 rue Combemale, Lille 59020, France.
Olmos D
Lacombe D
A'Hern R
Duhamel A
Twelves C
Marsoni S
Morales-Barrera R
Soria JC
Verweij J
Voest EE
Schöffski P
Schellens JH
Kramar A
Kristeleit RS
Arkenau HT
Kaye SB
Penel N
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2012 Sep 25; Vol. 107 (7), pp. 1025-30. Date of Electronic Publication: 2012 Aug 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Models, Statistical*
Clinical Trials, Phase I as Topic/*methods
Neoplasms/*blood
Neoplasms/*drug therapy
Platelet Count/*methods
Serum Albumin/*metabolism
Algorithms ; Decision Trees ; Endpoint Determination ; Female ; Humans ; Male ; Patient Selection ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression.
Autorzy:
Houthuijzen JM; Department of Medical Oncology, University Medical Center Utrecht, The Netherlands.
Daenen LG
Roodhart JM
Voest EE
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2012 Jun 05; Vol. 106 (12), pp. 1901-6. Date of Electronic Publication: 2012 May 17.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Drug Resistance, Neoplasm*
Mesenchymal Stem Cells/*physiology
Animals ; Cell Differentiation ; Disease Progression ; Humans ; Mesenchymal Stem Cells/drug effects ; Mesenchymal Stem Cells/metabolism ; Neoplastic Stem Cells ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastases.
Autorzy:
Snoeren N; Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.
van Hooff SR
Adam R
van Hillegersberg R
Voest EE
Guettier C
van Diest PJ
Nijkamp MW
Brok MO
van Leenen D
Koerkamp MJ
Holstege FC
Rinkes IH
Pokaż więcej
Źródło:
PloS one [PLoS One] 2012; Vol. 7 (11), pp. e49442. Date of Electronic Publication: 2012 Nov 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression Profiling*
Gene Expression Regulation, Neoplastic*
Colorectal Neoplasms/*pathology
Liver Neoplasms/*secondary
Aged ; Area Under Curve ; Cohort Studies ; Colorectal Neoplasms/metabolism ; Disease-Free Survival ; Female ; Humans ; Liver Neoplasms/metabolism ; Male ; Middle Aged ; Nucleic Acid Hybridization ; Oligonucleotide Array Sequence Analysis ; Proportional Hazards Models ; Recurrence ; Risk ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study.
Autorzy:
Ten Berg MJ (AUTHOR)
van den Bemt PM (AUTHOR)
Shantakumar S (AUTHOR)
Bennett D (AUTHOR)
Voest EE (AUTHOR)
Huisman A (AUTHOR)
van Solinge WW (AUTHOR)
Egberts TC (AUTHOR)
Ten Berg, Maarten J (AUTHOR)
van den Bemt, Patricia M L A (AUTHOR)
Shantakumar, Sumitra (AUTHOR)
Bennett, Dimitri (AUTHOR)
Voest, Emile E (AUTHOR)
Huisman, Albert (AUTHOR)
van Solinge, Wouter W (AUTHOR)
Egberts, Toine C G (AUTHOR)
Pokaż więcej
Źródło:
Drug Safety. 2011, Vol. 34 Issue 12, p1151-1160. 10p.
Czasopismo naukowe
Szczegóły
Tytuł:
miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.
Autorzy:
Holleman A; Vascular Biology Program, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Chung I
Olsen RR
Kwak B
Mizokami A
Saijo N
Parissenti A
Duan Z
Voest EE
Zetter BR
Pokaż więcej
Źródło:
Oncogene [Oncogene] 2011 Oct 27; Vol. 30 (43), pp. 4386-98. Date of Electronic Publication: 2011 May 09.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Gene Expression Regulation, Neoplastic*
Genes, APC*
Drug Resistance, Neoplasm/*genetics
MicroRNAs/*physiology
Paclitaxel/*pharmacology
Animals ; Carcinoma, Non-Small-Cell Lung/genetics ; Cell Line, Tumor ; Humans ; Lung Neoplasms/genetics ; Mice ; Mice, Nude ; Neoplasm Transplantation ; Up-Regulation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer.
Autorzy:
Molloy TJ; Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Devriese LA
Helgason HH
Bosma AJ
Hauptmann M
Voest EE
Schellens JH
van't Veer LJ
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2011 Jun 07; Vol. 104 (12), pp. 1913-9. Date of Electronic Publication: 2011 May 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplastic Cells, Circulating*
Breast Neoplasms/*pathology
Polymerase Chain Reaction/*methods
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/mortality ; Female ; Humans ; Immunomagnetic Separation ; Middle Aged ; Neoplasm Staging ; Prognosis ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Shared and separate functions of polo-like kinases and aurora kinases in cancer.
Autorzy:
Lens SM; Department of Medical Oncology and Cancer Genomics Centre, UMC Utrecht, Universiteitsweg 100, Stratenum 2. 118, Utrecht 3584 CG, The Netherlands. />Voest EE
Medema RH
Pokaż więcej
Źródło:
Nature reviews. Cancer [Nat Rev Cancer] 2010 Dec; Vol. 10 (12), pp. 825-41. Date of Electronic Publication: 2010 Nov 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Cell Cycle Proteins/*physiology
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein Serine-Threonine Kinases/*physiology
Proto-Oncogene Proteins/*physiology
Animals ; Aurora Kinase A ; Aurora Kinase B ; Aurora Kinases ; Cell Cycle Proteins/analysis ; Cell Cycle Proteins/antagonists & inhibitors ; Chromatids/physiology ; Cytokinesis ; Humans ; Kinetochores/physiology ; Mitosis ; Neoplasms/etiology ; Protein Serine-Threonine Kinases/analysis ; Protein Serine-Threonine Kinases/antagonists & inhibitors ; Proto-Oncogene Proteins/analysis ; Proto-Oncogene Proteins/antagonists & inhibitors ; Polo-Like Kinase 1
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Autorzy:
Snoeren N; Department of Surgical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Voest EE
Bergman AM
Dalesio O
Verheul HM
Tollenaar RA
van der Sijp JR
Schouten SB
Rinkes IH
van Hillegersberg R
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2010 Oct 11; Vol. 10, pp. 545. Date of Electronic Publication: 2010 Oct 11.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antibodies, Monoclonal/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*pathology
Colorectal Neoplasms/*therapy
Deoxycytidine/*analogs & derivatives
Fluorouracil/*analogs & derivatives
Liver Neoplasms/*secondary
Liver Neoplasms/*surgery
Organoplatinum Compounds/*administration & dosage
Angiogenesis Inhibitors/pharmacology ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/pharmacology ; Bevacizumab ; Capecitabine ; Chemotherapy, Adjuvant/methods ; Deoxycytidine/administration & dosage ; Disease-Free Survival ; Female ; Fluorouracil/administration & dosage ; Humans ; Male ; Neoplasm Metastasis ; Oxaliplatin ; Quality of Life ; Recurrence ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Are health care professionals able to judge cancer patients' health care preferences correctly? A cross-sectional study.
Autorzy:
Wessels H; 1Department of Corporate Communications, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands.
de Graeff A
Wynia K
de Heus M
Kruitwagen CL
Teunissen SC
Voest EE
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2010 Jul 08; Vol. 10, pp. 198. Date of Electronic Publication: 2010 Jul 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*
Patient Preference*
Health Personnel/*psychology
Adolescent ; Adult ; Aged ; Cross-Sectional Studies ; Female ; Forecasting ; Humans ; Male ; Middle Aged ; Professional-Patient Relations ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 83

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies